No quarterly revenue total was found in Indaptus Therapeutics, Inc.'s SEC filings.
Indaptus Therapeutics, Inc. (INDP) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
$-1.79M
+65.7% vs year-ago quarter
Operating cash flow
$-1.93M
+52.0% vs year-ago quarter
Free cash flow
—
EPS
$-0.02
+99.8% vs year-ago quarter
Dividend per share
None
Shares outstanding
133.24M
+11941.5% vs year-ago quarter
Net cash
$5.82M
Q3 FY2025
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INDP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1857044
- Former names
- Intec Parent Inc. (until Aug 3, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$1.8M | -$2.2M | -$8.2M | -$2.6M | -$4.5M |
| Net income | -$1.8M | -$2.5M | -$8.1M | -$3.0M | -$5.2M |
| Diluted EPS | -$0.02 | -$0.23 | -$4.54 | -$2.98 | -$9.09 |
| Operating cash flow | -$1.9M | -$7.0M | -$3.2M | -$2.6M | -$4.0M |
| Total assets | $12.0M | — | $9.3M | $6.8M | $6.8M |
| Total liabilities | $615,426 | — | — | — | — |
| Stockholders' equity | $11.4M | $1.2M | $3.2M | $4.6M | -$1.7M |
| Cash and investments | $11.6M | $1.5M | $8.5M | $5.8M | $6.2M |
| Total debt | — | — | — | $8,686 | $34,373 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 20, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 30, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Sep 10, 2026 | Sep 8, 2026 |
| 8-K/A |
Amended current report
Material agreement
|
Sep 8, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 4, 2026 | Sep 2, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 1, 2026 | Aug 28, 2026 |
All 343 Indaptus Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.